0
     

Report Added
Report already added
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

According to the recently published report 'Hepatocyte Growth Factor - Drugs In Development, 2022'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 19 molecules. Out of which approximately 19 molecules are developed by Companies.

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.

The report 'Hepatocyte Growth Factor - Drugs In Development, 2022' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 4, 1, 6 and 3 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Dermatology, Genetic Disorders, Hematological Disorders and Respiratory which include indications Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Amyotrophic Lateral Sclerosis, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Glioblastoma Multiforme (GBM), Melanoma, Ovarian Cancer, Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Spinal Cord Injury, Alzheimer's Disease, Anxiety Disorders, Arteriosclerosis, Breast Cancer, Charcot-Marie-Tooth Disease Type I A, Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), Chronic Kidney Disease (Chronic Renal Failure), Colon Cancer, Colorectal Cancer, Dementia, Depression, Diabetic Ischemic Foot Ulcers, Diabetic Neuropathic Pain, Diabetic Peripheral Neuropathy, Gallbladder Cancer, Gastric Cancer, Hepatocellular Carcinoma, Intermittent Claudication, Leiomyosarcoma, Lewy Body Dementia, Liver Fibrosis, Lung Cancer, Lung Injury, Lymphedema, Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Cancer, Myocardial Infarction, Nasopharyngeal Cancer, Neuromuscular Disorders, Non-Small Cell Lung Cancer, Occlusive Arterial Disease (OAD), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peripheral Artery Occlusive Disease (PAOD), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar, Schizophrenia, Solid Tumor, Thromboangiitis obliterans (Buerger disease) and Ulcers.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
- The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development
AnGes Inc
Athira Pharma Inc
AVEO Pharmaceuticals Inc
Beijing SH biotechnology Co Ltd
G&P Bioscience Co Ltd
Helixmith Co Ltd
i2 Pharmaceuticals Inc
Kringle Pharma Inc
Minerva Biotechnologies Corp
Molecular Partners AG
PlateletBio
Yichang Humanwell Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles
Ad-HGF - Drug Profile
Product Description
Mechanism Of Action
ATH-1020 - Drug Profile
Product Description
Mechanism Of Action
History of Events
beperminogene perplasmid - Drug Profile
Product Description
Mechanism Of Action
History of Events
donaperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
History of Events
ficlatuzumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
fosgonimeton - Drug Profile
Product Description
Mechanism Of Action
History of Events
GB-102 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate HGF for Liver Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to activate HGF for Lung Injury - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate HGF for Neuro Muscular Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to activate HGF for Peripheral Artery Occlusive Disease - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
MP-0250 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NK-4 - Drug Profile
Product Description
Mechanism Of Action
History of Events
oremepermin alfa - Drug Profile
Product Description
Mechanism Of Action
History of Events
SL-186 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SL-188 - Drug Profile
Product Description
Mechanism Of Action
History of Events
YYB-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones
Featured News & Press Releases
Jul 25, 2022: Athira Pharma to present clinical and preclinical data at Alzheimer’s Association International Conference 2022
Jun 22, 2022: Athira Pharma announces topline results from ACT-AD Phase 2 proof of concept study of Fosgonimeton in mild-to-moderate Alzheimer’s disease
May 09, 2022: Athira Pharma extends ongoing open label extension study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for mild to moderate Alzheimer’s Disease
May 02, 2022: Helixmith announces VM202 (Engensis) presentation at New York Academy of Sciences "Advances in Pain" Meeting on May 3, 2022
Apr 05, 2022: Athira doses first subject in Phase I neuropsychiatric treatment trial
Mar 30, 2022: Athira Pharma highlights strong execution of strategy and positioning for the future
Mar 20, 2022: Athira Pharma presents study overview and baseline data from ACT-AD phase 2 trial of Fosgonimeton in mild-to-moderate Alzheimer’s Disease at the 2022 AD/PD Congress
Mar 14, 2022: Athira Pharma to present overview and update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer’s disease at AD/PD 2022 Congress
Mar 14, 2022: Paper reporting results from Helixmith's phase 3 gene therapy trial for painful diabetic neuropathy was one of the top-10 most-downloaded articles in Clinical and Translational Science
Feb 22, 2022: Athira Pharma to present preclinical data at the American Society for Experimental Neurotherapeutics (ASENT) annual meeting
Feb 22, 2022: Athira Pharma to present preclinical data of fosgonimeton at the American Society for Experimental Neurotherapeutics (ASENT) annual meeting
Feb 22, 2022: Athira Pharma announces publication of phase 1 results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease
Jan 25, 2022: Athira Pharma announces initiation of patient dosing in SHAPE, a phase 2 clinical trial of ATH-1017 for the treatment of Parkinson's Disease dementia and dementia with lewy bodies
Dec 09, 2021: Kringle Pharma announces last patient out in phase 2 study of KP-100IT for the treatment of ALS
Nov 10, 2021: Athira Pharma presents overview and update from ACT-AD and LIFT-AD trials of ATH-1017 in mild-to-moderate Alzheimer’s disease at CTAD Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AnGes Inc, 2022
Pipeline by Athira Pharma Inc, 2022
Pipeline by AVEO Pharmaceuticals Inc, 2022
Pipeline by Beijing SH biotechnology Co Ltd, 2022
Pipeline by G&P Bioscience Co Ltd, 2022
Pipeline by Helixmith Co Ltd, 2022
Pipeline by i2 Pharmaceuticals Inc, 2022
Pipeline by Kringle Pharma Inc, 2022
Pipeline by Minerva Biotechnologies Corp, 2022
Pipeline by Molecular Partners AG, 2022
Pipeline by PlateletBio, 2022
Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2022
Pipeline by Yooyoung Pharm Co Ltd, 2022
Dormant Products, 2022
Discontinued Products, 2022

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline